argenx SE (FRA:1AE)

Market Cap	44.21B +16.7%
Revenue (ttm)	3.14B +93.0%
Net Income	1.31B
EPS	19.83
Shares Out	n/a
PE Ratio	33.83
Forward PE	26.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Average Volume	30
Open	719.40
Previous Close	718.60
Day's Range	716.40 - 719.40
52-Week Range	448.40 - 804.40
Beta	n/a
RSI	54.74
Earnings Date	Feb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 1,599
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1AE

Financial Performance

Financial numbers in USD